Table 3.2.5 Prevalence rates of coeliac disease as reported from various international studies.
Country | Screening method | Study size | Prevalence rate† | Authors and reference |
---|---|---|---|---|
The Netherlands | EMA* | 1 440 | 1 in 288 (a) | Schweizer JJ et al, 2004187 |
Australia | EMA | 3 011 | 1 in 251 (a) | Hovell CJ et al, 2001188 |
Sweden | TGA EMA | 1 850 | 1 in 205 (a) | Lagerqvist C et al, 2001189 |
The Netherlands | EMA | 6 127 | 1 in 198 (c) | Csizmadia CG et al, 1999190 |
Brazil | EMA | 2 371 | 1 in 183 (a) | Pratesi R et al, 2003191 |
Argentina | AGA EMA | 2 000 | 1 in 167 (a) | Gomez JC et al, 2001192 |
USA | AGA EMA | 4 126 | 1 in 133 (a) | Fasano A et al, 2003193 |
Finland | EMA | 1 070 | 1 in 130 (c) | Kolho KL et al, 1998194 |
Northern Ireland | AGA EMA | 1 823 | 1 in 122 (a) | Johnston SD et al, 1997195 |
Finland | EMA | 3 654 | 1 in 99 (c) | Maki M et al, 2003196 |
England | EMA* | 7 550 | 1 in 87 (a) | West J et al, 2003186 |
Europe (Finland, Germany, Italy, Northern Ireland) | TGA EMA | 29 268 | 1 in 50–1 in 220 (a) 1 in 88–1 in 123 (c) | Mustalahti K et al, 2004197 |
Determination in serum of IgA antibodies against gliadin (AGA), endomysium (EMA), and tissue transglutaminase (TGA).
*Diagnosis not confirmed by small bowel biopsy; †a, adults; c, children.